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Conclusions: The most common SUV descriptors as well as 
the volume of the involved lymph nodes of NSCLC patients 
are significant prognostic factors for overall survival for 
NSCLC. Likelihood of a worse prognosis increases with an 
increase of the mean SUV of the nodes. This is consistent 
with our hypothesis that there is more PET-related prognostic 
information in the nodes compared to the primary tumor.  
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Purpose/Objective: Stereotactic body radiotherapy (SBRT) is 
the treatment of choice in medically inoperable patients with 
stage I NSCLC. Today, SBRT is used with increasing frequency 
for pulmonary metastases: however, dose prescriptions are 
adapted from primary NSCLC experiences without their 
validation for metastases. It was therefore the aim of this 
study to analyze a potential dose-effect relationship for local 
tumor control in SBRT for pulmonary metastases and compare 
results to SBRT for stage I NSCLC. 
Materials and Methods: This retrospective multi-institutional 
study is based on 582 and 964 patients treated with SBRT for 
stage I NSCLC and pulmonary metastases at 13 centres; only 
patients with follow-up >6 months were analyzed resulting in 
399 and 525 patients, respectively. Patients with primary 
NSCLC and pulmonary metastases were treated with a 
median of 3 (range 1-17) and 3 (1-12) fractions to a total 
dose of 60Gy (range 19-86) and 55Gy (16-80) (maximum PTV 
dose at isocenter; PTV-max), respectively. BED was 
calculated using the LQ-model with α/β=10Gy resulting in 
PTV-max doses of 168Gy (48-263) and 138Gy (24-288) BED for 
primary NSCLC and metastases, respectively. Dose-effect 
models were compared using the second-order bias corrected 
Akaike Information Citerion (AICC). We used Bayesian logistic 
regression to estimate regression parameters and their 
standard errors. 
Results: Median tumor diameter was 2.6cm (0.8-4.8) and 
1.9cm (0.4-9.0) for patients with primary NSCLC and 
pulmonary metastases, respectively (p<0.001, Wilcoxon rank 
sum test); tumor diameter was lacking in 47% (primary 
NSCLC) and 12% (pulmonary metastases) of the patients. Most 
frequent histologies for pulmonary metastases were NSCLC 
(28%), colorectal (25%) and renal cell cancer (11%). Median 
follow-up was 19 months (6-139; primary NSCLC) and 16 
months (6-125; pulmonary metastases) (p=0.15). For 
pulmonary metastases, a strong dose response relationship 
was observed (evidence ratio 98.6), but only for PTV-max 
BED and not for the PTV encompassing BED; the latter is in 
contrast to findings from SBRT for primary NSCLC, where a 
strong evidence for a minimum PTV dose-effect was observed 
(Guckenberger et al. Radiother Oncol 2013). Overall, there 
was no difference in the dose response relationship between 
primary NSCLC and pulmonary metastases: the PTV-max BED 
required for 90% TCP was 176±17Gy and 167±18 Gy for 
primary NSCLC and pulmonary metastases, respectively. 
Conclusions: A significant dose-response relationship was 
observed in SBRT for pulmonary metastases with local tumor 
control as endpoint. The observed dose response relationship 
was not different to primary stage I NSCLC. We will, 
however, further investigate the influence of histology and 
tumor size on the dose-effect relationship in pulmonary 
metastases.  
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The incidence of breast cancer is rising in the elderly, 
reflecting the age related incidence of the disease and, in 
the UK, the impact  of  the breast screening programme. The 
evidence base for the role of postoperative radiotherapy (RT) 
after breast conserving surgery  in older patients has been 
limited, in part reflecting the historical exclusion of the 
elderly from randomised trials. Extrapolating outcomes from 
younger to older patients may not be valid. In older patients 
there are also competing risks of non breast cancer mortality. 
The Oxford overview (1) of over 10,000 women treated with 
breast conserving surgery with or without adjuvant 
radiotherapy shows that RT halves the risk of first recurrence 
(most of which are local). However the absolute reduction in 
risk of recurrence from RT is very modest in older good 
prognosis patients. The main source of level 1 evidence in 
older patients is the CALGB 9343 trial (1) which randomised 
over 700 women =/> 70 years with T1, NO,MO hormone 
receptor positive breast cancer treated by breast conserving 
